|
|
|
Insider
Information: |
Behbahani Ali |
Relationship: |
Director |
City: |
Timonium |
State: |
MD |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
19 |
|
Direct
Shares |
66,478 |
|
Indirect Shares
|
101,863,965 |
|
|
Direct
Value |
$429,595 |
|
|
Indirect Value
|
$389,581,950 |
|
|
Total
Shares |
101,930,443 |
|
|
Total
Value |
$390,011,545 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
6
|
0
|
Stock
price went up :
|
3
|
0
|
Stock
price went down : |
3
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
8.3%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Nevro Corp |
NVRO |
Director |
2018-05-21 |
5,390 |
2015-12-02 |
0 |
Premium* |
|
Crispr Therapeutics Ag |
CRSP |
Director |
2020-08-13 |
256 |
2020-08-13 |
14 |
Premium* |
|
Adaptimmune Therapeutics PLC |
ADAP |
Director |
2018-09-07 |
0 |
2020-01-24 |
19,500,000 |
Premium* |
|
Genocea Biosciences, Inc. |
GNCA |
Director, 10% Owner |
2019-02-14 |
0 |
2022-05-25 |
0 |
Premium* |
|
Regulus Therapeutics Inc. |
RGLS |
10% Owner |
2019-05-07 |
0 |
2020-12-04 |
6,451,056 |
Premium* |
|
Trevi Therapeutics, Inc. |
TRVI |
10% Owner |
2019-05-09 |
0 |
2022-04-11 |
948,948 |
Premium* |
|
Mirum Pharmaceuticals, Inc. |
MIRM |
10% Owner |
2019-07-22 |
0 |
2023-06-13 |
135 |
Premium* |
|
Black Diamond Therapeutics, Inc. |
BDTX |
|
2024-03-15 |
51,690 |
2024-03-15 |
4,448,757 |
Premium* |
|
Oyster Point Pharma, Inc. |
OYST |
Director |
2023-01-03 |
0 |
2020-06-08 |
0 |
Premium* |
|
Akouos, Inc. |
AKUS |
10% Owner |
2020-06-30 |
0 |
2022-11-30 |
0 |
Premium* |
|
Metacrine, Inc. |
MTCR |
10% Owner |
2020-09-18 |
0 |
2021-12-22 |
2,563,257 |
Premium* |
|
Savara Inc |
SVRA |
10% Owner |
|
0 |
2023-07-17 |
24,471,264 |
Premium* |
|
Marker Therapeutics Inc |
MRKR |
10% Owner |
2021-03-16 |
0 |
2021-03-16 |
10,714,285 |
Premium* |
|
Monte Rosa Therapeutics, Inc. |
GLUE |
Director, 10% Owner |
2021-06-28 |
0 |
2021-06-28 |
7,692,298 |
Premium* |
|
Bright Health Group Inc. |
BHG |
10% Owner |
2021-06-28 |
0 |
2021-06-28 |
23,983,073 |
Premium* |
|
Minerva Surgical Inc |
UTRS |
Director |
2021-10-26 |
8,487 |
2021-10-26 |
0 |
Premium* |
|
Arcellx, Inc. |
ACLX |
Director |
2023-06-01 |
339 |
2023-06-01 |
85 |
Premium* |
|
Korro Bio |
KRRO |
|
2023-11-03 |
0 |
2024-04-22 |
1,090,793 |
Premium* |
|
Cvrx, Inc. |
CVRX |
Director |
2023-12-14 |
316 |
2023-12-14 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
69 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
SVRA |
Savara Inc |
10% Owner |
|
2021-03-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
24,137,931 |
|
% |
|
NVRO |
Nevro Corp |
Director |
|
2015-12-02 |
4 |
A |
$0.00 |
$0 |
D/D |
25 |
25 |
0 |
- |
|
NVRO |
Nevro Corp |
Director |
|
2016-11-11 |
4 |
A |
$0.00 |
$0 |
D/D |
22 |
47 |
0 |
- |
|
NVRO |
Nevro Corp |
Director |
|
2017-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,518 |
1,565 |
0 |
- |
|
NVRO |
Nevro Corp |
Director |
|
2017-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
40 |
1,605 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
199 |
199 |
0 |
- |
|
NVRO |
Nevro Corp |
Director |
|
2018-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
3,785 |
5,390 |
0 |
- |
|
TRVI |
Trevi Therapeutics, Inc. |
10% Owner |
|
2019-05-09 |
4 |
A |
$0.00 |
$0 |
I/I |
1,938,562 |
1,938,562 |
0 |
- |
|
MIRM |
Mirum Pharmaceuticals, In... |
10% Owner |
|
2019-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
3,736,243 |
3,736,243 |
0 |
- |
|
BDTX |
Black Diamond Therapeutic... |
Director |
|
2020-02-03 |
4 |
A |
$0.00 |
$0 |
I/I |
2,648,757 |
2,648,757 |
0 |
- |
|
OYST |
Oyster Point Pharma, Inc. |
Director |
|
2020-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
6,600 |
6,600 |
0 |
- |
|
AKUS |
Akouos, Inc. |
10% Owner |
|
2020-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
3,705,972 |
3,705,972 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2020-08-13 |
4 |
A |
$0.00 |
$0 |
D/D |
57 |
256 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2020-08-13 |
4 |
A |
$0.00 |
$0 |
I/I |
14 |
14 |
0 |
- |
|
MTCR |
Metacrine, Inc. |
10% Owner |
|
2020-09-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,291,297 |
2,291,297 |
0 |
- |
|
OYST |
Oyster Point Pharma, Inc. |
Director |
|
2021-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,466 |
10,066 |
0 |
- |
|
GLUE |
Monte Rosa Therapeutics, ... |
Director |
|
2021-06-28 |
4 |
A |
$0.00 |
$0 |
I/I |
6,642,298 |
6,642,298 |
0 |
- |
|
BHG |
Bright Health Group Inc. |
10% Owner |
|
2021-06-28 |
4 |
A |
$0.00 |
$0 |
I/I |
69,963,828 |
22,288,629 |
0 |
- |
|
TRVI |
Trevi Therapeutics, Inc. |
10% Owner |
|
2021-10-18 |
4 |
B |
$0.00 |
$0 |
I/I |
1,851,852 |
7,789,850 |
1.42 |
- |
|
UTRS |
Minerva Surgical Inc |
Director |
|
2021-10-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,487 |
8,487 |
0 |
- |
|
OYST |
Oyster Point Pharma, Inc. |
Director |
|
2022-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,573 |
13,639 |
0 |
- |
|
AKUS |
Akouos, Inc. |
10% Owner |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,294,207) |
0 |
0 |
- |
|
ACLX |
Arcellx, Inc. |
Director |
|
2022-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
226 |
226 |
0 |
- |
|
ACLX |
Arcellx, Inc. |
Director |
|
2022-12-20 |
4 |
A |
$0.00 |
$0 |
I/I |
57 |
57 |
0 |
- |
|
OYST |
Oyster Point Pharma, Inc. |
Director |
|
2023-01-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,639) |
0 |
0 |
- |
|
69 Records found
|
|
Page 1 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|